During its recently-held Annual General Meeting, Gerresheimer approved a dividend of EUR 0.65 per share. The company also presented strong results for financial year 2012.
A dividend of EUR 0.65 per share was approved at the Annual General Meeting of Gerresheimer AG held on 18 April in Düsseldorf, Germany. The company, a leading partner to the pharma and healthcare industry, presented a strong set of results for financial year 2012.
“In financial year 2012, our business with the pharmaceutical industry once again achieved strong growth rates and proved to be relatively immune to economic cycles. Sales of primary packaging glass, as well as plastic products and drug delivery devices, developed very dynamically. Our strategy is geared to sustained, profitable growth. We plan to further extend our leading position in Europe and North America and generate strong growth in emerging markets,” said Uwe Röhrhoff, CEO of Gerresheimer AG, summarizing the strategy at the Annual General Meeting.
In the prior year, a dividend of EUR 0.60 per share was distributed.
The following resolutions were adopted at the Annual General Meeting, at which some 69.42% of the share capital was represented:
- ITEM 2: Appropriation of the retained earnings for financial year 2012 – 99.99% votes in favour
- ITEM 3: Formal approval of the actions of the Management Board for financial year 2012 – 98.28% votes in favour
- ITEM 4: Formal approval of the actions of the Supervisory Board for financial year 2012 – 97.44% votes in favour
- ITEM 5: Election of the auditor for financial year 2013 – 99.96% votes in favour
The speech delivered at the Annual General Meeting is available at:
The online annual report is available at: http://annualreport2012.gerresheimer.com
Gerresheimer is a leading international manufacturer of high-quality specialty products made of glass and plastic for the global pharma and healthcare industry. Our comprehensive product portfolio extends from pharmaceutical vials to complex drug delivery systems such as syringe systems, insulin pens and inhalers for safe medication dosage and application. Together with our partners, we develop groundbreaking solutions that set standards across the industry.
With some 11,000 employees at 47 locations in Europe, North and South America and Asia, the Group generates revenues of around EUR 1.2 billion.